Substantial Variability Exists in International Consensus Definitions for Pediatric ALL Trial Outcomes
Researchers sought to address the variability in definitions for key outcomes in trials involving pediatric ALL.
Diagnosis & Disease Information
Incidence and Risk Factors Identified for Secondary Neoplasms After HSCT for Patients With Sickle Cell Disease
Researchers sought to determine the risk factors for patients with SCD developing a secondary neoplasm after undergoing HSCT.
Charlson-Deyo Comorbidity Index Independent Predictor of Survival in Acute Promyelocytic Leukemia
Researchers sought to show an association between Charlson-Deyo Comorbidity Index and survival outcomes.
Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Vemurafenib Retreatment May Be Effective in Hairy Cell Leukemia
Researchers sought to determine whether vemurafenib retreatment would be effective in patients with relapsed or refractory hairy cell leukemia long-term.
Patient-Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists.
AstraZeneca Will Withdraw Leukemia Drug Lumoxiti From US Market
Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.
Race, Ethnicity, Obesity Have No Significant Impact on CAR-T Therapy Efficacy in B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR-T therapy in patients with B-ALL.
Olverembatinib Shows Promise in TKI-Resistant CML and Ph+ ALL
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
- Loading...
Loading...
Loading... 
Loading...